Benefits
Digestive symptom relief with the heat-inactivated form
In 443 adults with IBS, two capsules a day of heat-inactivated cells (1 billion in total) for 8 weeks met the main outcome, at least 30% less abdominal pain plus adequate relief in at least 4 of 8 weeks, in 34% versus 19% on placebo. Adequate relief alone was 60% versus 44%. The product's company funded the trial.
Digestive symptom scores with the live form
In 122 adults with IBS, live cells once a day for 4 weeks lowered a daily global symptom score by 0.88 points on a 7-point scale versus 0.16 on placebo, and 47% versus 11% reported adequate relief. The strain patent names this score as the main outcome, and two authors are the strain's patent inventors.
Abdominal discomfort, bloating and urgency scores
In the 4-week trial of live cells, the abstract reports significant improvement in pain or discomfort, distension or bloating, urgency and digestive disorder scores, without stating each comparison with placebo. In the 8-week trial of heat-inactivated cells, pain was counted as part of the combined main outcome, and the abstract does not report pain alone.
Quality of life and mental well-being scores
In the live-cell trial, SF-12 quality of life scores rose within the probiotic group; the abstract gives no comparison with placebo. In the heat-inactivated trial, the registry results report a larger rise in the SF-12 mental health score than on placebo (3.3 versus 1.7 points, p = 0.031), a secondary outcome the registry named only after the trial ended.
Mechanism of action
Adhesion to human intestinal cells (lab work)
In lab tests, MIMBb75 stuck strongly to Caco-2 and HT-29 human colon cell lines, and adhesion changed with sugars, bile salts and pH. A surface protein, BopA, was first proposed as the adhesin, but a later study that blocked BopA found adhesion did not fall. These are cell results, not human outcomes.
Barrier signals in cell culture, live and heat-inactivated
In a Caco-2 cell model, both live and heat-inactivated MIMBb75 raised transepithelial electrical resistance, a lab sign of a tighter cell layer, and the strain kept its high surface hydrophobicity after heat treatment. Synformulas funded this study and helped design it. It does not show a barrier effect in people.
Immune cell signaling (lab work)
MIMBb75 and TgaA, an enzyme on its cell surface, activated dendritic cells in lab experiments and triggered interleukin-2 production, with one domain of the enzyme (CHAP) carrying the activity. This describes how the strain may interact with immune cells, not an effect shown in people.
Passage through the gut (animal work)
In mice given 100 million CFU a day for 2 weeks, the live strain colonized the gut for a short time, mainly the cecum and upper colon, and shifted some resident bacterial groups. Mouse results may not carry over to people.
Clinical trials
Randomized, double-blind, placebo-controlled multicenter trial; live B. bifidum MIMBb75 (60 people) or placebo (62) once a day for 4 weeks, symptoms rated daily on a 7-point scale; the strain patent describes the study capsules as 1 billion CFU; the abstract names no primary outcome or registry number, but the strain patent names the change in this global score as the primary endpoint, analyzed in all randomized patients and does not name the funder, though PubMed indexes it as having non-government research support; Guglielmetti and Mora are the strain's patent inventors, and PubMed lists no affiliation for the other two authors (Guglielmetti et al. 2011, Aliment Pharmacol Ther)
122 adults with IBS.
The global symptom score fell by 0.88 points on MIMBb75 versus 0.16 on placebo (p < 0.0001). The abstract also reports significant improvement in pain or discomfort, distension or bloating, urgency and digestive disorder, without stating each comparison with placebo. Adequate relief was reported by 47% versus 11%, and overall responders were 57% versus 21%. Adverse events did not differ from placebo.
Randomized, double-blind, placebo-controlled trial at 20 sites in Germany; two capsules a day with a combined 1 billion non-viable B. bifidum MIMBb75 cells or placebo for 8 weeks; registered before recruitment as ISRCTN14066467, where the main outcome is worded as response at the end of treatment, without the 30% and 4 of 8 weeks rules, and the posted registry results give the same 33.5% versus 19.4% under that wording; a response at week 8 alone is not reported; the primary analysis counted all 443 randomized people; after the trial ended, the registry's list of secondary outcomes was cut from eight to two; funded by Synformulas, which is the registry contact; the three authors are listed at German hospitals (Andresen et al. 2020, Lancet Gastroenterol Hepatol)
443 adults with IBS (Rome III) and abdominal pain of at least 4 on a 0 to 10 scale on at least 2 days during run-in; 221 product, 222 placebo.
The main outcome, at least 30% less abdominal pain plus adequate relief in at least 4 of 8 weeks, was met by 34% on the product versus 19% on placebo (risk ratio 1.7, p = 0.0007). No serious adverse events occurred on the product; 7 product-related adverse events were suspected on the product and 8 on placebo. Live and heat-inactivated forms were not compared directly. In the registry results, adequate relief alone was reported by 60.2% versus 44.1% (p = 0.0009).